Achieving an Itch-Free State With Upadacitinib: A Post-Hoc Analysis of Data From the Phase 2b Randomized, Double-Blind, Placebo-Controlled Trial in Moderate-to-Severe Atopic Dermatitis

Jonathan I Silverberg1, Kristian Reich1, Brian Calimlim1, Yihua Gu1, Xiaofei Hu1, Henrique D Teixeira1, Emma Gutman-Yassky1

1Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States; 2Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, and Skinflammation1 Center, Hamburg, Germany; AbbVie Inc, North Chicago, Illinois, United States; 3Icahn School of Medicine at the Mount Sinai Medical Center, New York, New York, United States

Presented at the Revolutionizing Atopic Dermatitis (RAD) 2020 Virtual Congress, April 5, 2020, Chicago, Illinois

OBJECTIVES

• To compare the proportions of upadacitinib-treated patients achieving an itch-free state vs placebo

BACKGROUND

• Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by pruritus and eczematous lesions
• The selective Janus Kinase 1 inhibitor, upadacitinib (UPA), is being investigated for treatment of AD and other immune-mediated diseases

METHODS

STUDY DESIGN

Table 1. Demographics and Baseline Characteristics

<table>
<thead>
<tr>
<th>Group</th>
<th>Placebo (n = 41)</th>
<th>UPA 7.5 mg QD (n = 42)</th>
<th>UPA 15 mg QD (n = 42)</th>
<th>UPA 30 mg QD (n = 42)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, n(%)</td>
<td>13 (43)</td>
<td>7 (17)</td>
<td>13 (31)</td>
<td>14 (31)</td>
</tr>
<tr>
<td>Age (mean, SD)</td>
<td>49 ± 19</td>
<td>48 ± 19</td>
<td>39 ± 15</td>
<td>39 ± 15</td>
</tr>
<tr>
<td>Race, n(%)</td>
<td>White (69)</td>
<td>Asian (21)</td>
<td>Asian (21)</td>
<td>Asian (21)</td>
</tr>
<tr>
<td>EASI, mean (SD)</td>
<td>24 ± 13</td>
<td>21 ± 6 (90)</td>
<td>24 ± 15</td>
<td>24 ± 15</td>
</tr>
<tr>
<td>POEM, mean (SD)</td>
<td>34 ± 18 (98)</td>
<td>34 ± 18 (98)</td>
<td>34 ± 18 (98)</td>
<td>34 ± 18 (98)</td>
</tr>
<tr>
<td>Pre-baseline</td>
<td>UPA 15 mg (n = 42) UPA 30 mg (n = 42)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>1:1:1:1 randomization</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 2. Identifying an Itch-Free State

• Patients assessed their overall symptom severity using a single-item Patient Global Impression of Severity (PGIS) scale
• Distribution patterns of Pruritus NRS by PGIS suggest that Pruritus NRS ≤ 1 is a reasonable threshold for identifying patients whose overall symptom severity is absent or minimal

Figure 3. % Patients With POEM Itch = 0 (zero days of itch in past week)

CONCLUSIONS

• Upadacitinib treatment for 16 weeks resulted in significant improvements in pruritus vs placebo
• Upadacitinib-treated subjects achieved a higher proportion and duration of an itch-free state vs placebo
• The positive benefit:risk profile of upadacitinib supports proceeding to phase 3 trials in AD

REFERENCES